MicuRx Pharmaceuticals’ MRX-8 Achieves Positive Results in Phase I Clinical Study
MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has announced the successful completion...
Drug
Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Recommended for Approval by EMA’s CHMP
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company based in Guangzhou, has received notification that the...
Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing...
Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...
Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval...
Legend Biotech’s Carvykti Shows Durable Responses in Multiple Myeloma Patients Post ASCT
Legend Biotech Corporation (NASDAQ: LEGN) has announced results from the Phase II CARTITUDE-2 Cohort D...
CSPC Pharmaceutical Secures NMPA Nod for Generic Version of AstraZeneca’s Lynparza
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns
FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...
Gilead and Arcus Biosciences Report Positive Interim Phase II Data for Domvanalimab Combo in GI Cancers
Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced interim Phase II data for...
Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors
Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical...
Bristol Myers Squibb’s Krazati Meets Primary Endpoint in Late-Stage Lung Cancer Study
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that a late-stage study for its KRAS...
Pfizer’s Lorbrena Outperforms Xalkori in 5-Year ALK-Positive NSCLC Follow-Up
Pfizer Inc. (NYSE: PFE) has announced the release of five-year follow-up data for its kinase...
Astellas Resubmits FDA Application for Vyloy as Treatment for CLDN18.2-Positive Cancer
Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has resubmitted its first-in-class anti-CLDN18.2 biologic...
Simcere Pharma’s Suvemcitug Shows Positive Results in Platinum-Resistant Ovarian Cancer Study
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has presented updated data...
Ascentage Pharma’s APG-2449 Shows Positive Results in ROS1 and ALK Positive NSCLC at ASCO 2024
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in Suzhou, has announced a wall poster...
Jacobio Pharma’s KRAS G12C Inhibitor Combo Shows Promising Results in NSCLC at ASCO 2024
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, presented updated data at the...
Innovent Biologics Presents Clinical Data for Pipeline Candidates at ASCO 2024
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, presented updates on several...
Gilead’s Trodelvy Misses Overall Survival Endpoint in Late-Stage Urothelial Cancer Study
Gilead (NASDAQ: GILD) has announced that a late-stage study for its antibody-drug conjugate (ADC) Trodelvy...
Chipscreen’s Chidamide in Sight of Breakthrough Therapy Designation in China for MSS/pMMR Colorectal Cancer
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...
Simcere Pharma’s Anti-Insomnia Drug Daridorexant Meets Primary Endpoint in Phase III Clinical Trial
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced topline results from a Phase III...